Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK

被引：0
|
作者：
Karnon, J
Delea, TE
Papo, NL
Barghout, V
Thomas, SK
Johnston, SR
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Policy Anal Inc, Brookline, MA USA
[3] Novartis Pharmaceut UK Ltd, Camberley, England
[4] Novartis Pharmaceut Corp, Florham Pk, NJ USA
[5] Novartis Pharmaceut Corp, E Hanover, NJ USA
[6] Royal Marsden Hosp, London SW3 6JJ, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67270-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A43 / A43
页数：1
相关论文
共 50 条
  • [21] Intermittent letrozole as adjuvant treatment in postmenopausal hormone-receptor positive early breast cancer patients
    Balduzzi, A.
    Bagnardi, V.
    Volpe, S.
    Cancello, G.
    Iorfida, M.
    Dellapasqua, S.
    Sandri, M.
    Goldhirsch, A.
    Colleoni, M.
    CANCER RESEARCH, 2013, 73
  • [22] Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
    Butani, Dimple
    Gupta, Nidhi
    Jyani, Gaurav
    Bahuguna, Pankaj
    Kapoor, Rakesh
    Prinja, Shankar
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 625 - 640
  • [23] Cost effectiveness analysis of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer
    Hashem, I.
    Al-Sherbini, M.
    El-Bary, N. Abd
    Swiha, M.
    BREAST, 2009, 18 : S78 - S78
  • [24] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Karnon, Jonathan
    Delea, Thomas
    Barghout, Vicki
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (02): : 171 - 183
  • [25] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Jonathan Karnon
    Thomas Delea
    Vicki Barghout
    The European Journal of Health Economics, 2008, 9
  • [26] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
    El Ouagari, K.
    Kamon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
  • [27] Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jonathan
    Smith, Robert E.
    Johnston, Stephen R. D.
    Brandman, Jane
    Sung, Jennifer C. Y.
    Goss, Paul E.
    AMERICAN JOURNAL OF MANAGED CARE, 2006, 12 (07): : 374 - 386
  • [28] Applying survival based cost-effectiveness analyses to estimate the impact of patent expiry on the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer
    Karnon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2010, 8 (03): : 66 - 66
  • [29] Cost-effectiveness of anastrozole versus tamoxifen for the treatment of post menopausal hormone-receptor positive Breast Cancer (BC) in the adjuvant setting in Brazil
    Fonseca, M.
    Araujo, G.
    Saad, E.
    VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [30] Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer
    Karnon, Jonathan
    Johnston, Stephen R.
    Delea, Tom
    Smith, Robert
    Brandman, Jane
    Sung, Jennifer
    ANNALS OF ONCOLOGY, 2004, 15 : 63 - 63
12345